ClinicalTrials.gg
CompletedNCT01323257Updated Oct 11, 2012

TMC435-TiDP16-C115 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Erythromycin and Between TMC435 and Darunavir/Ritonavir (DRV/r)

A Phase 1 interventional study of erythromycin and Ritonavir in Hepatitis C Virus, sponsored by Tibotec Pharmaceuticals, Ireland. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-10-11.

Sponsored by Tibotec Pharmaceuticals, Ireland (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing ritonavir in Hepatitis C — none open to participants now, 1 under way, none of them phase 3. Ritonavir · Hepatitis C.

Enrollment
10th of 22
49 · median 48
Started
2011
with 2 others
Phase 1
7 of 22
none open now
Registered
4th of 22
by date
Lead sponsor
2 of 22
Tibotec Pharmaceuticals, Ireland

Among the 22 studies testing ritonavir in Hepatitis C, this one is the 10th largest by enrollment, is one of 3 that started in 2011, is one of 7 in phase 1, and was the 4th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

None of the 22 studies testing ritonavir in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →

About ritonavir

Ritonavir: first FDA approval 1996 (NORVIR), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 22 studies testing ritonavir in Hepatitis C as a file.
02

Study summary

The purpose of this study is to investigate the effect of steady-state concentrations of erythromycin or DRV/r on the steady-state pharmacokinetics of TMC435, the effect of a steady-state concentration of TMC435 (150 mg) on the steady-state pharmacokinetics of erythromycin and the effect of a steady-state concentration of TMC435 (50 mg) on the steady-state pharmacokinetics of DRV/r. We will also study the short-term safety and tolerability of TMC435 given alone and given togehter with erythromycin (Panel 1) or DRV/r (Panel 2). Steady state is a term that means that the drug has been given long enough so that the plasma concentrations will remain the same with each subsequent dose. TMC435 is being investigated for the treatment of chronic hepatitis C virus (HCV) infection. Pharmacokinetics (PK) means how the drug is absorbed into the bloodstream, distributed in the body, and eliminated from the body.

Read the detailed description

TMC435 is being investigated for treatment of chronic hepatitis C virus (HCV) infection, in combination with Peg-IFN (pegylated interferon) and RBV (ribavirin). Erythromycin is an antibiotic and Darunavir/ritonavir (DRV/r) is currently indicated for the treatment of HIV infection. TMC435 is metabolized by the degradation enzyme CYP3A. Erythromycin and DRV/r are respectively moderate and strong inhibitors of the degradation enzyme CYP3A. The result of this study will provide dosing recommendations for TMC435 and for erythromycin or DRV/r, when being coadministered. This is a Phase I, open-label (both participant and investigator know the name of the medication given at certain moment), randomized (sequence of treatment with study medications is assigned by chance), crossover trial in 48 healthy volunteers to investigate the pharmacokinetic interaction between TMC435, at steady state, and DRV/r or erythromycin, at steady-state. The volunteers will be allocated to one of two panels. In Panel 1, volunteers will receive three treatments (Trts A, B and C) in a randomized order. Volunteers will receive TMC435 150 mg once daily for 7 days (Trt A) and erythromycin 500 mg three times daily for 6 days + a morning dose on day 7 (Trt B) and TMC435 150 mg once daily for 7 days + erythromycin 500 mg three tmes daily for 7 days (Trt C). In Panel 2, volunteers will receive three treatments (Trts D, E and F) in a randomized order. Volunteers will receive TMC435 150 mg once daily for 7 days (Trt D), DRV/r 800/100 mg once daily for 7 days (Trt E) and TMC435 50 mg once daily for 7 days + DRV/r 800/100 mg once daly for 7 days (Trt F). In both panels, there will be a washout period (a period when no study drug will be taken, in order to have all the medication eliminated from the body before starting a new treatment) of at least 10 (Panel 1) or 7 (Panel 2) days between last intake of the study medication in one session and the first intake of study medication in the subsequent session. Pharmacokinetic profiles of all four compounds (TMC435, DRV, ritonavir and erythromycin) will be determined through blood samples taken at regular intervals during the study. Safety and tolerability will be assessed during the study period and during follow up. Blood and urine samples, electrocardiogram (ECG) and vital signs (blood pressure and heart rate) will be taken at screening, on Day 1, Day 7 and Day 8 and at the follow up visit at 1 week after last dose of study medication in the last session. A physical examination will be performed at screening, on Day -1 (= day before first medication intake in each session for both panels) or Day 1, on Day 8 and during the follow-up visit. Volnteers will be admitted to the unit on Day-1, discharged on Day2, re-admitted on Day6 and discharged again on Day8. Each volunteer follows 3 treatment (Trt) periods, which are a minimum 10 days (Panel 1) or 7 days (Panel 2) apart from each other. All treatment periods take 7 days and all drugs are for oral intake. Panel 1: Trt A = 150 mg TMC435 once daily; Trt B = 500 mg erythromycin three times daily; Trt C: combining Trt A + B. Panel 2: Trt D = Trt A; Trt E = 800/100 mg DRV/r once daily; Trt D = 50 mg TMC435 once daily + Trt E.

03

Conditions studied

  • Hepatitis C Virus

Browse trials for

Keywords

  • TMC435-TiDP16-C115
  • TMC435-C115
  • TMC435
  • HCV
  • Hepatitis C
  • Hep C
  • healthy volunteers
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-smoker for at least 3 months
  • of 18.0 to 30.0 kg/m2
  • Healthy based on a medical evaluation including medical history, physical examination, blood tests, vital signs, and

Exclusion criteria

Exclusion Criteria:

  • Infection with hepatitis A, B or C virus
  • Infection with the (HIV)
  • History of or any current medical condition which could impact the safety of the participant in the study
  • Having previously been dosed with TMC435 in a multiple-dose trial with TMC435
  • Having previously been dosed with TMC435 in more than 3 single-dose trials with TMC435
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    001

    TMC435 150 mg capsule once daily for 7 days (Trt A C D)

    Drug: TMC435

  • Experimental
    002

    erythromycin 500 mg tablets three times a day for 6 days + 1 morning dose for 7th day (Trt B)

    Drug: erythromycin

  • Experimental
    003

    erythromycin 500 mg tablets three times a day for 7 days (Trt C)

    Drug: erythromycin

  • Experimental
    004

    TMC435 50 mg capsule once daily for 7 days (Trt F)

    Drug: TMC435

  • Experimental
    005

    Darunavir 2 x 400 mg tablet once daily for 7 days (Trt E F)

    Drug: Darunavir

  • Experimental
    006

    Ritonavir 100 mg tablet once daily for 7 days (Trt E F)

    Drug: Ritonavir

Interventions

  • 500 mg tablets three times a day for 6 days + 1 morning dose for 7th day (Trt B)

  • 100 mg tablet once daily for 7 days (Trt E, F)

  • DrugTMC435

    150 mg capsule once daily for 7 days (Trt A, C, D)

  • 2 x 400 mg tablet once daily for 7 days (Trt E, F)

  • DrugTMC435

    50 mg capsule once daily for 7 days (Trt F)

  • 500 mg tablets three times a day for 7 days (Trt C)

06

What researchers measure

Primary outcomes

  1. Change in the steady-state plasma pharmacokinetics of TMC435 following co-administration with erythromycin (Panel 1).

    Time frame: Measured on Day 1 and Day 5-10 (Trt C). Reference for TMC435 is on Day 1 and Day 5-10 of Trt A.

  2. Change in the steady-state plasma pharmacokinetics of TMC435 following co-administration with DRV/r (Panel 2).

    Time frame: Measured on Day 1 and Day 5-10 (Trt F). Reference for TMC435 is on Day 1 and Day 5-10 of Trt D.

Secondary outcomes

  1. Change in the steady-state plasma pharmacokinetics of erythromycin following co-administration with TMC435 (Panel 1).

    Time frame: Measured on Day 1 and Day 5-7 (Trt C). Reference for erythromycin is on Day 1 and Day 5-7 of Trt B.

  2. Change in the steady-state plasma pharmacokinetics of DRV/r following co-administration with TMC435 (Panel 2).

    Time frame: Measured on Day 1 and Day 5-8 (Trt F). Reference for DRV/r is on Day 1 and Day 5-8 of Trt E.

  3. Number of participants with adverse events as a measure of safety and tolerability - TMC435 and erythromycin

    Time frame: Up to Day 67

  4. Number of participants with adverse events as a measure of safety and tolerability - TMC435 and DRV/r

    Time frame: Up to Day 61

07

Study locations

1 site
  • Antwerpen, Belgium
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2011
First posted
Mar 25, 2011
Start
Mar 2011
CompletionActual
Aug 2011
Last update
Oct 11, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 11, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01323257
Responsible party
Sponsor
First posted
Mar 25, 2011
Start date
Mar 2011
Completion
Aug 2011
Last update
Oct 11, 2012

Study contacts

Tibotec Pharmaceuticals Clinical Trial
study director · Tibotec Pharmaceutical Limited

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Erythromycin · Ritonavir · Simeprevir · Darunavir

Start the discussion